Abdullah Hussain

Mr. Abdullah Hussain

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2026 in Biosensors
Verified
Journal Article
Open access
PDF file
YWYahya Waly
Yahya Waly
AHAbdullah Hussain
Abdullah Hussain
Abdulrahman Al-MajmueiAbdulrahman Al-Majmuei
Abdulrahman Al-Majmuei
Mohammad AlatoomMohammad Alatoom
Mohammad Alatoom
AAAhmed AlAraibi
Ahmed AlAraibi
Roshan DeenRoshan Deen
Roshan Deen
Diabetes is a chronic metabolic disorder that poses a growing global health challenge, currently affecting nearly 500 million people. Over the past four decades, the rising prevalence of diabetes has highlighted the urgent need for innovations in monitoring and management. Traditional enzymatic methods, including those using glucose oxidase, glucose dehydrogenase, and hexokinase, are widely adopted due to their specificity and relative ease of use. However, they are hindered by issues of instability, environmental sensitivity, and interference from other biomolecules. Non-enzymatic sensors, which employ metals and nanomaterials for the direct oxidation of glucose, offer an attractive alternative. These platforms demonstrate higher sensitivity and cost-effectiveness, though they remain under refinement for routine use. Non-invasive glucose detection represents a futuristic leap in diabetes care. By leveraging alternative biofluids such as saliva, tears, sweat, and breath, these methods promise enhanced patient comfort and compliance. Nonetheless, their limited sensitivity continues to challenge widespread adoption. Looking forward, the integration of nanotechnology, wearable biosensors, and artificial intelligence paves the way for personalized, affordable, and patient-centered diabetes management, marking a transformative era in healthcare. This review explores the evolution of glucose monitoring, from early chemical assays to advanced state-of-the-art nanotechnology-based approaches.

11 September 2025 in AACE Endocrinology and Diabetes
Verified
Journal Article
Open access
LKLoay Kamel
Loay Kamel
AHAbdullah Hussain
Abdullah Hussain
AEAhmed Elmewafy
Ahmed Elmewafy
DADalal Ali
Dalal Ali
AKAliya A. Khan
Aliya A. Khan
X-linked hypophosphatemia (XLH) is a disorder caused by a pathogenic variant in the phosphate-regulating endopeptidase homolog X-linked gene. This leads to increased fibroblast growth factor 23 synthesis, prompting renal phosphate wasting and hypophosphatemia. Adults with XLH present with osteomalacia, chronic musculoskeletal pain, enthesopathy, osteoarthritis, fractures, and pseudofractures. We present a patient initially diagnosed with hypophosphatemic, nonrachitic bone disease. However, later genetic testing identified a pathogenic phosphate-regulating endopeptidase homolog X-linked variant (c.1645+1G>A), establishing an XLH diagnosis. A 50-year-old male was diagnosed with XLH through molecular testing at age 49. He was initially diagnosed at age 3 years with hypophosphatemic bone disease due to an unclear inheritance pattern. Treatment with phosphate and active vitamin D was started but discontinued at age 13 due to adverse effects, then resumed between ages 30 and 45. The patient presented with joint pain, abnormal gait, dental abscesses, and right hip replacement due to early-onset osteoarthritis with history of an atraumatic vertebral fracture at age 42. Labs showed hypophosphatemia, low tubular phosphate reabsorption, and elevated alkaline phosphatase and fibroblast growth factor 23. He was switched to burosumab therapy, resulting in clinical improvement. This case underscores the diagnostic challenges of atypical XLH, particularly when X-linked inheritance patterns are absent. It illustrates the transformative role of molecular diagnostics in establishing diagnoses. It also reports on the impact of burosumab therapy when initiated in adults. This case demonstrates hallmark biochemical and radiological features of XLH, and the value of genetic testing in establishing a definitive diagnosis, particularly in individuals with atypical or nonclassical presentations.

22 October 2026 in Cosmetics
Verified
Journal Article
Open access
PDF file
AAAhmed Abdulkarim Y. Alaysereen
Ahmed Abdulkarim Y. Alaysereen
AHAbdullah Hussain
Abdullah Hussain
BHBushra Hasan
Bushra Hasan
AZAli Zayer
Ali Zayer
AKAbdu-Alaziz Khaskieh
Abdu-Alaziz Khaskieh
AAAysha Almoosa
Aysha Almoosa
Background: Atrophic acne scars are challenging to treat and have a negative psychological impact. Insulin has been tried as a topical adjuvant and stimulates fibroblast activity, collagen deposition, and keratinocyte migration. Objectives: To evaluate topical insulin for atrophic acne scars in terms of its effectiveness, safety, and patient-rated results. Methods: Five databases were searched for research on topical insulin, either alone or in conjunction with a procedure, without regard to the date. Records were screened, extracted, and evaluated in duplicate (RoB 2 or ROBINS-I) each by two independent researchers, using Covidence. Results: Fourteen studies with 619 patients, seven randomized and seven non-randomized, were qualified. All insulin arms improved from baseline (35.8% to 55.4%), but comparator arms mostly improved similarly; five studies, none at low risk of bias, favored insulin. Adverse effects were mostly local, minor, and transient, although one study reported systemic hypoglycemia-related symptoms; glucose monitoring was inconsistent, and satisfaction was high. Limitations: Meta-analysis was not possible due to heterogeneity in design, dosage, and outcome scales, and the small number of patients precludes certain conclusions. Conclusions: Although its superiority over current adjuncts has not been demonstrated, topical insulin appears to be an affordable, well-tolerated adjunct that may have a function where traditional therapies are unavailable; larger studies are needed.

1 January 2026 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
AEAhmed Elmewafy
Ahmed Elmewafy
EJEyad Jamileh
Eyad Jamileh
AHAbdullah Hussain
Abdullah Hussain
LKLoay Kamel
Loay Kamel
OFOmar Farooq
Omar Farooq
IAIbrahim Antoun
Ibrahim Antoun
Introduction: Heart‐type fatty acid‐binding protein (H‐FABP) is rapidly released following myocardial injury, but its prognostic significance in acute coronary syndrome (ACS) remains uncertain. We evaluated the association between elevated H‐FABP and adverse clinical outcomes in confirmed or suspected ACS. Methods: PubMed, Embase, CENTRAL, Web of Science and Scopus were searched from inception to 30 August 2026 without date restriction. Studies assessing diagnostic and/or prognostic relevance of circulating H‐FABP in adults with confirmed or suspected ACS were eligible. Prognostic outcomes included all‐cause mortality, major adverse cardiovascular events (MACE), heart failure (HF)–related hospitalisation and recurrent myocardial infarction (MI). Risk of bias was assessed using QUIPS. Crude odds ratios (ORs) from extractable 2 × 2 event data were pooled using inverse‐variance random‐effects models with restricted maximum‐likelihood estimation. Results: Twelve studies were included, with five contributing to meta‐analysis. Elevated H‐FABP was associated with higher odds of all‐cause mortality (OR 5.68; 95% CI 3.98–8.09; I 2 = 30 % ), MACE (OR 4.56; 95% CI 1.97–10.55; I 2 = 47 % ), HF‐related hospitalisation (OR 4.29; 95% CI 2.94–6.26; I 2 = 0 % ) and recurrent MI (OR 1.65; 95% CI 1.15–2.37; I 2 = 0 % ). Pooled estimates were unadjusted; seven studies were synthesised narratively. Conclusion: Elevated H‐FABP is associated with adverse outcomes in ACS, but current evidence does not establish independent prognostic value. Further prospective studies should determine whether H‐FABP adds predictive value beyond established clinical and biochemical risk markers.